Case selection for statins was similar in two Canadian provinces: BC and Ontario.

[1]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[2]  J. Avorn,et al.  Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. , 2004, The New England journal of medicine.

[3]  Thomas E. Feasby,et al.  Variations in rates of appropriate and inappropriate carotid endarterectomy for stroke prevention in 4 Canadian provinces , 2004, Canadian Medical Association Journal.

[4]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[5]  T. Walley,et al.  Variations and increase in use of statins across Europe: data from administrative databases , 2004, BMJ : British Medical Journal.

[6]  S. Morgan.  Sources of variation in provincial drug spending. , 2004, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[7]  P. Austin,et al.  Secondary prevention after acute myocardial infarction in four Canadian provinces, 1997-2000. , 2004, The Canadian journal of cardiology.

[8]  A. Laupacis,et al.  Gaps in the evaluation and monitoring of new pharmaceuticals: proposal for a different approach. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[9]  J. Tu,et al.  Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001. , 2003, The Canadian journal of cardiology.

[10]  Peter Tanuseputro,et al.  Risk factors for cardiovascular disease in Canada. , 2003, The Canadian journal of cardiology.

[11]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[12]  B. O'brien,et al.  Rapid increase in statins newly dispensed to Ontario seniors between 1994 and 2000. , 2003, Canadian Journal of Cardiology.

[13]  Paul Grootendorst,et al.  Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. , 2003, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

[14]  L. Pilote,et al.  The effects of cost-sharing on essential drug prescriptions, utilization of medical care and outcomes after acute myocardial infarction in elderly patients. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[15]  J. Tu,et al.  Adherence With Statin Therapy in Elderly Patients With and Without Acute Coronary Syndromes , 2002 .

[16]  D. Cook,et al.  Use of statins in the secondary prevention of coronary heart disease: is treatment equitable? , 2002, Heart.

[17]  J. Heineke,et al.  Does More “Appropriateness” Explain Higher Rates of Cardiac Procedures Among Patients Hospitalized With Coronary Heart Disease? , 2002, Medical care.

[18]  Janet E Hux,et al.  Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. , 2002, Diabetes care.

[19]  P. Grootendorst.  Beneficiary cost sharing under Canadian provincial prescription drug benefit programs: history and assessment. , 2002, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

[20]  A. Kazanjian,et al.  Utilization of lipid-lowering drugs in men and women. a reflection of the research evidence? , 2002, Journal of clinical epidemiology.

[21]  James G Wright,et al.  Determining the Need for Hip and Knee Arthroplasty: The Role of Clinical Severity and Patients’ Preferences , 2001, Medical care.

[22]  J A Hanley,et al.  Adverse events associated with prescription drug cost-sharing among poor and elderly persons. , 2001, JAMA.

[23]  A. Majeed,et al.  Age, sex and practice variations in the use of statins in general practice in England and Wales. , 2000, Journal of public health medicine.

[24]  A R Levy,et al.  Coding accuracy of hospital discharge data for elderly survivors of myocardial infarction. , 1999, The Canadian journal of cardiology.

[25]  L. Corr,et al.  Time trend analysis and variations in prescribing lipid lowering drugs in general practice , 1998, BMJ.

[26]  H. Krumholz,et al.  Improving the quality of care for Medicare patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. , 1998, JAMA.

[27]  C. Naylor,et al.  Appropriateness of primary total hip and knee replacements in regions of Ontario with high and low utilization rates. , 1996, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[28]  J. Simons,et al.  Apparent discontinuation rates in patients prescribed lipid‐lowering drugs , 1996, The Medical journal of Australia.

[29]  R. Tamblyn,et al.  The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Québec. , 1995, Journal of clinical epidemiology.

[30]  R H Brook,et al.  Does inappropriate use explain small-area variations in the use of health care services? , 1990, JAMA.

[31]  R H Brook,et al.  Does inappropriate use explain geographic variations in the use of health care services? A study of three procedures. , 1987, JAMA.

[32]  R H Brook,et al.  Variations in the use of medical and surgical services by the Medicare population. , 1986, The New England journal of medicine.

[33]  N. Roos,et al.  Elective surgical rates--do high rates mean lower standards? Tonsillectomy and adenoidectomy in Manitoba. , 1977, The New England journal of medicine.